

AMENDMENTS TO THE CLAIMS

1-16. (Cancelled).

17. (Previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence encoding the hSARS virus having China Center for Type Culture Collection Deposit Accession No. CCTCC-V200303, or a complement thereof.

18-26. (Cancelled).

27. (Previously presented) The nucleic acid molecule of claim 17 or 146, wherein the molecule is RNA.

28-29. (Cancelled).

30. (Previously presented) The nucleic acid molecule of claim 17 or 146, wherein the molecule is DNA.

31-100. (Cancelled).

101. (Currently amended) ~~An immunogenic~~ A pharmaceutical formulation comprising ~~an immunogenically effective amount of~~ a nucleic acid molecule comprising at least 8,000 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or [[a]] the full-length complement thereof, ~~encoding a SARS antigen~~; and a pharmaceutically acceptable carrier.

102-124. (Cancelled).

125. (Previously Presented) A kit comprising a container containing the immunogenic formulation of claim 101.

126-145. (Cancelled).

146. (Previously presented) An isolated nucleic acid molecule comprising a nucleotide sequence having at least 8,000 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15, or a complement thereof.

147-173. (Cancelled).

174. (Previously presented) The nucleic acid molecule of claim 146 having the nucleotide sequence of SEQ ID NO:15.

175. (Currently amended) [[A]] An isolated host cell comprising the isolated nucleic acid molecule of claim 17 or 146.

176. (Previously presented) The host cell of claim 175, which is a primate cell.

177. (Previously presented) The host cell of claim 176, which is a FRhK-4 fetal rhesus monkey kidney cell.

178. (Cancelled).